.Attribute Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in boosted progression-free as well as overall survival, bring about FDA approval and a brand new procedure choice for clients.